Trending NewsTrending NewsNASDAQ:IMMX Immix Biopharma (IMMX) Stock Price, News & Analysis $10.54 -0.93 (-8.11%) Closing price 09/29/2026 04:00 PM EasternExtended Trading$10.58 +0.04 (+0.42%) As of 09/29/2026 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Immix Biopharma Stock (NASDAQ:IMMX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Immix Biopharma alerts:Sign Up Key Stats Today's Range$10.07▼$11.8550-Day Range$8.17▼$14.4752-Week Range$1.99▼$15.10Volume5.76 million shsAverage Volume1.36 million shsMarket Capitalization$754.03 millionP/E RatioN/ADividend YieldN/APrice Target$24.14Consensus RatingModerate Buy Company Overview Immix Biopharma, Inc. (NASDAQ: IMMX) is a clinical-stage biopharmaceutical company developing cell therapies for cancer and autoimmune diseases. The company focuses on treatments designed to target disease-associated cells and address serious conditions with limited therapeutic options. Its lead product candidate is NXC-201, an autologous chimeric antigen receptor T-cell (CAR-T) therapy targeting B-cell maturation antigen (BCMA). NXC-201 is being investigated for relapsed or refractory AL amyloidosis and multiple myeloma, two diseases involving abnormal plasma cells. The candidate is intended to direct a patient’s modified immune cells against cells expressing BCMA. Immix Biopharma was founded in 2012 and is headquartered in Los Angeles, California. The company’s clinical development activities have included work in the United States and Australia. Ilya Rachman serves as the company’s chief executive officer and has been involved in its development since its founding.AI Generated. May Contain Errors. Read More Immix Biopharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks67th Percentile Overall ScoreIMMX MarketRank™: Immix Biopharma scored higher than 67% of companies evaluated by MarketBeat, and ranked 264th out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingImmix Biopharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.78, and is based on no strong buy ratings, 8 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialImmix Biopharma has a consensus price target of $24.14, representing about 129.1% upside from its current price of $10.54.Amount of Analyst CoverageImmix Biopharma has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Immix Biopharma's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Immix Biopharma are expected to grow in the coming year, from ($0.73) to ($0.62) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Immix Biopharma is -11.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Immix Biopharma is -11.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioImmix Biopharma has a P/B Ratio of 5.95. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Immix Biopharma's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted19.30% of the float of Immix Biopharma has been sold short.Short Interest Ratio / Days to CoverImmix Biopharma has a short interest ratio ("days to cover") of 7.75.Change versus previous monthShort interest in Immix Biopharma has recently increased by 0.05%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldImmix Biopharma does not currently pay a dividend.Dividend GrowthImmix Biopharma does not have a long track record of dividend growth. News and Social Media4.4 / 5News Sentiment1.06 News SentimentImmix Biopharma has a news sentiment score of 1.06. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.75 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 18 news articles for Immix Biopharma this week, compared to 3 articles on an average week.Search Interest4 people have searched for IMMX on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows1 people have added Immix Biopharma to their MarketBeat watchlist in the last 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Immix Biopharma insiders have not sold or bought any company stock.Percentage Held by Insiders30.30% of the stock of Immix Biopharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions11.26% of the stock of Immix Biopharma is held by institutions.Read more about Immix Biopharma's insider trading history. Receive IMMX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Immix Biopharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IMMX Stock News HeadlinesTranscript : Immix Biopharma, Inc. - Shareholder/Analyst CallSeptember 29 at 5:32 PM | marketscreener.comMImmix Biopharma's NXC-201 Shows 89% Complete Response Rate In AL AmyloidosisSeptember 29 at 5:32 PM | rttnews.comThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business. | Porter & Company (Ad)ImmixBio Reports 89% CR Rate, Potential 98% With NXC-201 In AL AmyloidosisSeptember 29 at 5:32 PM | rttnews.comImmix Biopharma Announces 89% Complete Response Rate at Interim Update Across All NEXICART-2 Patients, with MRD-Negativity Indicating Potential to Reach up to 98% Complete ...September 29 at 5:32 PM | markets.businessinsider.comImmix Biopharma prices $125M stock offeringSeptember 29 at 5:32 PM | msn.comImmix Biopharma Reports 89% Complete Response Rate in Phase 2 NXC-201 TrialSeptember 29 at 5:32 PM | finance.yahoo.comBofA raises odds of success for Immix Biopharma’s NXC-201 therapy — sees over 190% upside in IMMX stockSeptember 29 at 5:32 PM | msn.comSee More Headlines IMMX Stock Analysis - Frequently Asked Questions How have IMMX shares performed this year? Immix Biopharma's stock was trading at $5.23 at the beginning of 2026. Since then, IMMX stock has increased by 101.5% and is now trading at $10.54. How were Immix Biopharma's earnings last quarter? Immix Biopharma, Inc. (NASDAQ:IMMX) announced its quarterly earnings results on Friday, August, 7th. The company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.17) by $0.01. When did Immix Biopharma IPO? Immix Biopharma (IMMX) raised $23 million in an initial public offering on Thursday, December 16th 2021. The company issued 4,200,000 shares at a price of $5.00-$6.00 per share. How do I buy shares of Immix Biopharma? Shares of IMMX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Immix Biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Immix Biopharma investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), Jabil (JBL), Disc Medicine (IRON), e.l.f. Beauty (ELF) and Adobe (ADBE). Company Calendar Last Earnings8/07/2026Today9/29/2026Study result9/29/2026Next Earnings (Estimated)11/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (10m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 IMMX's financial health is in the Green zone, according to TradeSmith. IMMX has been in this zone for over 10 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:IMMX CIK1873835 Webwww.immixbio.com Phone310-651-8041FaxN/AEmployees21Year Founded2012Price Target and Rating Average Price Target for Immix Biopharma$24.14 High Price Target$30.00 Low Price Target$19.00 Potential Upside/Downside+129.1%Consensus RatingModerate Buy Rating Score (0-4)2.78 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)($0.88) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$29.44 million Net MarginsN/A Pretax MarginN/A Return on Equity-38.44% Return on Assets-34.72% Debt Debt-to-Equity RatioN/A Current Ratio25.13 Quick Ratio25.13 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.77 per share Price / Book5.95Miscellaneous Outstanding Shares71,540,000Free Float49,863,000Market Cap$754.03 million OptionableOptionable Beta0.20 Social Links The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NASDAQ:IMMX) was last updated on 9/30/2026 by MarketBeat.com Staff. From Our PartnersA “bloodbath” Is ComingReports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...TradeSmith | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredShould You Convert a Traditional IRA to a Roth After 60?Considering a Roth conversion after 60? The upside includes no income limits on conversions, potential tax-fre...SmartAsset | SponsoredMusk says UBI is coming. I say it's already here.Elon Musk says AI could make money irrelevant by 2036. One income program already exists today, funded not by ...Freedom Financial | SponsoredManagement just bought 2.8 million sharesManagement just backed a $100 million buyback, repurchasing 2.8 million shares at an average price of $35.26 i...Monument Traders Alliance | SponsoredNew Chip takes minutes, not daysGeorge Gilder believes today's AI data centers could become tomorrow's typewriters - replaced by a single wafe...Eagle Publishing | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immix Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immix Biopharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
